leadf
logo-loader
viewRUA Life Sciences
(
AIM:RUA
)

AorTech International: Accelerating development of its novel heart valve and graft products

AorTech International plc's (LON:AOR) Bill Brown introduces the company to Proactive London's Andrew Scott.

He says the business is based on a platform technology material called Elast-Eon which he says has been in human use for close to 15 years.

They licence out the tech as well as develop their own products using it.

He says they've now begun the manufacture of heart valves and early prototype valves are currently available for evaluation plus they're also nearing animal trials for its graft development programme.

Quick facts: RUA Life Sciences

Follow
AIM:RUA

Price: 134.5 GBX

Market Cap: £29.84 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read